Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1852 results
November 2018
-
Story Discovery
Artificial intelligence decodes cancer pathology images without image gallery
Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.
-
Story Discovery
Artificial intelligence decodes cancer pathology images
Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.
-
Press release
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker… -
Story From Our Labs
Women in Science: Wendy Winckler
Meet Wendy Winckler, Executive Director of Oncology Research at Novartis.
-
Story From Our Labs
Women in Science: Jennifer Allport-Anderson
Cardiovascular researcher Jennifer Allport-Anderson describes the personal qualities and decisions that have made her a successful leader.
-
Story From Our Labs
Women in Science: Jean Silveri
Jean Silveri shares key insights from her legal career.
-
Story From Our Labs
Women in Science: Cyndy Grosskreutz
Physician-scientist Cyndy Grosskreutz explains why she transitioned from academia to industry.
-
Story From Our Labs
Women in Science: Alexandra Bach-Weidmuller
Alexandra Bach-Weidmuller, Head of Program and Project Management at NIBR, describes her path to leadership as lateral instead of upward.
-
Press release
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
26 potential blockbusters in confirmatory development[1]. 13 projects in clinical development across Cell, Gene & Radioligand therapies. 60 major submissions[2] planned from 2019 to 2021… -
Press release
Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is… -
Press release
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2-… -
Story Patient Perspectives
The realities of living with premenopausal metastatic breast cancer
Receiving a breast cancer diagnosis is difficult, but these young women faced an especially challenging diagnosis: stage IV metastatic breast cancer.